Related Experiment Video
Updated: Dec 6, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes
Eduardo Bello Martins1, Eduardo Gomes Lima1, Fábio Grunspun Pitta1
1Departamento de Aterosclerose, Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, USP (InCor-HCFMUSP).
Abstract:
The pharmacological therapy for type 2 diabetes mellitus has presented important advances in recent years, which has impacted the treatment of patients with established cardiovascular disease or with high cardiovascular risk. In this scenario, two drug classes have emerged and demonstrated clear clinical benefits: SGLT-2 inhibitors and GLP-1 agonists. The present review discusses the pharmacology, adverse effects, and clinical trials that have demonstrated the benefits of these medications in reducing cardiovascular risk.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Atherosclerosis III: Management
Diabetes Mellitus: Type 2 and Gestational
Hypertension IV: Drug Therapy and Lifestyle Modifications
Heart Failure V: Medical Management
Coronary Artery Disease V: Interprofessional Care

